Evidence map›Paper›PMID 32419935›Full record

Trial reportEuropean journal of hospital pharmacy : science and practice2020

Two regimens of dexamethasone versus prednisolone for acute exacerbations in asthmatic Egyptian children.

Dalia A Elkharwili, Osama M Ibrahim, Gamal A Elazab, Shaymaa M Elrifaey

Open access · bronzeAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in European journal of hospital pharmacy : science and practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Therapeutic Strategies in the Management of COVID-19.Frontiers in molecular biosciences · 2020
    Review
  7. COVID-19 Therapeutic Options Under Investigation.Frontiers in pharmacology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Dalia A ElkharwiliClinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Osama M IbrahimClinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Gamal A ElazabClinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Shaymaa M ElrifaeyPediatrics Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Tanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Asthma is one of the most prevalent chronic respiratory diseases, which often leads to an emergency department visit. Prednisolone is the most commonly used corticosteroid in treatment of asthma exacerbation. Oral dexamethasone demonstrates bioavailability similar to that of oral prednisolone but has a longer half-life. Objective: To evaluate in adouble-blind, randomised clinical trial the efficacy of different doses of dexamethasone versus prednisolone in controlling asthma exacerbations in children. Methods: We recruited 60 patients with asthma exacerbation, aged 2-11 years. Participants were randomly divided into three groups (20 patients each). Group I received a single dose of oral dexamethasone 0.3 mg/kg (maximum 12 mg), group II received 0.6 mg/kg/day of oral dexamethasone for 2 days (maximum 16 mg/day) and group III received 1.5 mg/kg/day oral prednisolone for 5 days (maximum 60 mg/day). Our primary outcomes were changes in Paediatric Respiratory Assessment Measure (PRAM), eosinophilic count and serum immunoglobulin E on day 5. Secondary endpoints were reporting any adverse effects and relapse rate during the 5 days. After 30 days, the Asthma Therapy Assessment Questionnaire (ATAQ) was given to the parents of the recruited patients. Results: Among the three study groups, there was a highly statistically significant difference in IgE level, saturated oxygen, peak expiratory flow, forced expiratory volume in 1 s/forced vital capacity, PRAM and Modified Pulmonary Index Score; however, the eosinophilic count was significantly lower within the same group. Vomiting, gastrointestinal tract cramps, ATAQ and relapse rate showed a non-statistically significant difference. Conclusion: Single-dose dexamethasone was at least as effective as 5-day course of prednisolone in controlling asthma, while dexamethasone for 2 days was non-inferior to 5 days of prednisolone in children with asthma exacerbation.

Indexed as

Acute DiseaseAdministration, OralAnti-Asthmatic AgentsAsthmaChildChild, PreschoolDexamethasoneDose-Response Relationship, DrugDouble-Blind MethodEgyptFemaleForced Expiratory VolumeGlucocorticoidsHumansMalePrednisoloneAnti-Asthmatic AgentsDexamethasoneGlucocorticoidsPrednisoloneAdverse EffectsClinical PharmacyPaediatricsPharmacologyRespiratory Medicine (see Thoracic Medicine)

Identifiers

PMID32419935
PMCPMC7223341
OpenAlexW2900957524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.